Truist raises Agios Pharmaceuticals price target to $39, citing pipeline and commercial progress
Truist Securities has increased its 12-month price target for Agios Pharmaceuticals to $39 from $38 while maintaining a Buy rating. The move follows the company’s fourth-quarter 2025 results and updates on late-stage program planning and early commercial activity. Agios reported strong growth in PYRUKYND revenue and is advancing mitapivat filings i…